Autres langues Leap Therapeutics, Inc.

Actions

LPTX

US52187K2006

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
2,63 ^USD	-4,01 %		-5,40 %	-36,55 %

14/05	LEAP THERAPEUTICS, INC. : HC Wainwright reste à l'achat	ZM
13/05	Leap Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Leap Therapeutics Announces $40 Million Private Placement	11/04
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	10/04
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration	18/03
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium	16/01
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients	02/01
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients	02/01
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium	12/12
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference	21/11
Leap Therapeutics Reports Third Quarter 2023 Financial Results	13/11
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Top Premarket Decliners	16/10/23
Top Premarket Decliners	09/10/23
Leap Therapeutics to Participate at Upcoming Investor Conferences	05/09/23
Leap Therapeutics Reports Second Quarter 2023 Financial Results	15/08/23
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients	12/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Leap Therapeutics, Inc.

Actions

LPTX

US52187K2006

Autres langues

Filtres